1
|
Tsubaki M, Takeda T, Matsuda T, Seki S, Tomonari Y, Koizumi S, Nagatakiya M, Katsuyama M, Yamamoto Y, Tsurushima K, Ishizaka T, Nishida S. Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells. Biomedicines 2021; 9:33. [PMID: 33406639 DOI: 10.3390/biomedicines9010033] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/14/2020] [Accepted: 12/30/2020] [Indexed: 11/16/2022] Open
Abstract
Multiple myeloma (MM) is an incurable malignancy often associated with primary and acquired resistance to therapeutic agents, such as proteasome inhibitors. However, the mechanisms underlying the proteasome inhibitor resistance are poorly understood. Here, we elucidate the mechanism of primary resistance to bortezomib and ixazomib in the MM cell lines, KMS-20, KMS-26, and KMS-28BM. We find that low bortezomib and ixazomib concentrations induce cell death in KMS-26 and KMS-28BM cells. However, high bortezomib and ixazomib concentrations induce cell death only in KMS-20 cells. During Gene Expression Omnibus analysis, KMS-20 cells exhibit high levels of expression of various genes, including anti-phospho-fibroblast growth factor receptor 1 (FGFR1), chemokine receptor type (CCR2), and serum and glucocorticoid regulated kinase (SGK)1. The SGK1 inhibitor enhances the cytotoxic effects of bortezomib and ixazomib; however, FGFR1 and CCR2 inhibitors do not show such effect in KMS-20 cells. Moreover, SGK1 activation induces the phosphorylation of NF-κB p65, and an NF-κB inhibitor enhances the sensitivity of KMS-20 cells to bortezomib and ixazomib. Additionally, high levels of expression of SGK1 and NF-κB p65 is associated with a low sensitivity to bortezomib and a poor prognosis in MM patients. These results indicate that the activation of the SGK1/NF-κB pathway correlates with a low sensitivity to bortezomib and ixazomib, and a combination of bortezomib and ixazomib with an SGK1 or NF-κB inhibitor may be involved in the treatment of MM via activation of the SGK1/NF-κB pathway.
Collapse
|
2
|
Jeong YH, Li W, Go Y, Oh YC. Atractylodis Rhizoma Alba Attenuates Neuroinflammation in BV2 Microglia upon LPS Stimulation by Inducing HO-1 Activity and Inhibiting NF-κB and MAPK. Int J Mol Sci 2019; 20:E4015. [PMID: 31426492 DOI: 10.3390/ijms20164015] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 08/11/2019] [Accepted: 08/15/2019] [Indexed: 02/06/2023] Open
Abstract
Microglial activation and the resulting neuroinflammation are associated with a variety of brain diseases, such as Alzheimer’s disease and Parkinson’s disease. Thus, the control of microglial activation is an important factor in the development of drugs that can treat or prevent inflammation-related neurodegenerative disorders. Atractylodis Rhizoma Alba (ARA) has been reported to exhibit antioxidant, gastroprotective, and anti-inflammatory effects. However, the effects of ARA ethanolic extract (ARAE) on microglia-mediated neuroinflammation have not been fully elucidated. In this work, we explored the anti-neuroinflammatory properties and underlying molecular mechanisms of ARAE in lipopolysaccharide (LPS)-stimulated microglial BV2 cells. Our results showed that ARAE significantly attenuates the production of nitric oxide (NO) and inflammatory cytokines induced by LPS. ARAE treatment also inhibited the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 without causing cytotoxicity. ARAE markedly attenuated the transcriptional activities of nuclear factor (NF)-κB and mitogen-activated protein kinases (MAPK) phosphorylation, and induced heme oxygenase (HO)-1 expression. High-performance liquid chromatography (HPLC) analysis showed that ARAE contains three main components—atractylenolide I, atractylenolide III, and atractylodin—all compounds that significantly inhibit the production of inflammatory factors. These findings indicate that ARAE may be a potential therapeutic agent for the treatment of inflammation-related neurodegenerative diseases.
Collapse
|
3
|
Yang Y, Wang Y, Kong Y, Zhang X, Zhang H, Gang Y, Bai L. Mechanical stress protects against osteoarthritis via regulation of the AMPK/NF-κB signaling pathway. J Cell Physiol 2018; 234:9156-9167. [PMID: 30311192 PMCID: PMC6587477 DOI: 10.1002/jcp.27592] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2018] [Accepted: 09/18/2018] [Indexed: 12/29/2022]
Abstract
Mechanical stress plays a key role in regulating cartilage degradation in osteoarthritis (OA). The aim of this study was to evaluate the effects and mechanisms of mechanical stress on articular cartilage. A total of 80 male Sprague‐Dawley rats were randomly divided into eight groups (n = 10 for each group): control group (CG), OA group (OAG), and CG or OAG subjected to low‐, moderate‐, or high‐intensity treadmill exercise (CL, CM, CH, OAL, OAM, and OAH, respectively). Chondrocytes were obtained from the knee joints of rats; they were cultured on Bioflex 6‐well culture plates and subjected to different durations of cyclic tensile strain (CTS) with or without exposure to interleukin‐1β (IL‐1β). The results of the histological score, immunohistochemistry, enzyme‐linked immunosorbent assay, and western‐blot analyses indicated that there were no differences between CM and CG, but OAM showed therapeutic effects compared with OAG. However, CH and OAH experienced more cartilage damage than CG and OAG, respectively. CTS had no therapeutic effects on collagen II of normal chondrocytes, which is consistent with findings after treadmill exercise. However, CTS for 4 hr could alleviate the chondrocyte damage induced by IL‐1β by activating AMP‐activated protein kinase (AMPK) phosphorylation and suppressing nuclear translocation of nuclear factor (NF)‐κB p65. Our findings indicate that mechanical stress had no therapeutic effects on normal articular cartilage and chondrocytes; mechanical stress only caused damage with excessive stimulation. Still, moderate biomechanical stress could reduce sensitization to the inflammatory response of articular cartilage and chondrocytes through the AMPK/NF‐κB signaling pathway.
Collapse
Affiliation(s)
- Yue Yang
- Department of Orthopedic Surgery, Shengjing Hospital, China Medical University, ShenYang, Liaoning, China
| | - Yang Wang
- Department of Ultrasound, Shengjing Hospital, China Medical University, ShenYang, Liaoning, China
| | - Yawei Kong
- International Patient Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Xiaoning Zhang
- Department of Orthopedic Surgery, Shengjing Hospital, China Medical University, ShenYang, Liaoning, China
| | - He Zhang
- Department of Orthopedic Surgery, Shengjing Hospital, China Medical University, ShenYang, Liaoning, China
| | - Yi Gang
- Department of Orthopedic Surgery, Shengjing Hospital, China Medical University, ShenYang, Liaoning, China
| | - Lunhao Bai
- Department of Orthopedic Surgery, Shengjing Hospital, China Medical University, ShenYang, Liaoning, China
| |
Collapse
|
4
|
Giopanou I, Lilis I, Papadaki H, Papadas T, Stathopoulos GT. A link between RelB expression and tumor progression in laryngeal cancer. Oncotarget 2017; 8:114019-114030. [PMID: 29371965 PMCID: PMC5768382 DOI: 10.18632/oncotarget.23109] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Accepted: 07/25/2017] [Indexed: 12/31/2022] Open
Abstract
Laryngeal cancer is a frequent malignancy originating from the squamous vocal epithelium in a multi-stage fashion in response to environmental carcinogens. Although most cases can be cured by surgery and/or radiotherapy, advanced and relapsing disease is common, and biomarkers of such dismal cases are urgently needed. The cancer genome of laryngeal cancers was recently shown to feature a signature of aberrant nuclear factor (NF)-κB activation, but this finding has not been clinically exploited. We analyzed primary tumor samples of 96 well-documented and longitudinally followed patients covering the whole spectrum of laryngeal neoplasia, including 21 patients with benign laryngeal diseases, 15 patients with dysplasia, 43 patients with early-stage carcinoma, and 17 patients with locally advanced carcinoma, for immunoreactivity of RelA, RelB, P50, and P52/P100, the main NF-κB subunits that activate transcription. Results were cross-examined with indices of tumor progression and survival. Interestingly, RelB expression increased with tumor stage, grade, and local extent. Moreover, patients displaying high RelB immunoreactivity exhibited statistically significantly poorer survival compared with patients featuring low levels of RelB expression (P = 0.018 by log-rank test). Using Cox regression analyses and tumor stage, local extent, grade and RelA/RelB immunoreactivity, we develop a new score that can independently predict survival of patients with laryngeal cancer. Hence we provide a simple and affordable NF-κB-based test to predict prognosis in laryngeal cancer.
Collapse
Affiliation(s)
- Ioanna Giopanou
- Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Achaia 26504, Greece
| | - Ioannis Lilis
- Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Achaia 26504, Greece
| | - Helen Papadaki
- Department of Anatomy, Faculty of Medicine, University of Patras, Rio, Achaia 26504, Greece
| | - Theodoros Papadas
- Department of Otorhinolaryngology & Head and Neck Surgery, Faculty of Medicine, University of Patras, Rio, Achaia 26504, Greece
| | - Georgios T Stathopoulos
- Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Achaia 26504, Greece.,Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), University Hospital, Ludwig-Maximilians University and Helmholtz ZentrumMünchen, Member of The German Center for Lung Research (DZL), Munich, Bavaria 81377, Germany
| |
Collapse
|
5
|
Wang WC, Xia YM, Yang B, Su XN, Chen JK, Li W, Jiang T. Protective Effects of Tyrosol against LPS-Induced Acute Lung Injury via Inhibiting NF-κB and AP-1 Activation and Activating the HO-1/Nrf2 Pathways. Biol Pharm Bull 2017; 40:583-593. [PMID: 28190857 DOI: 10.1248/bpb.b16-00756] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Tyrosol (Tyr) is a natural antioxidant that displays anti-oxidant and anti-inflammatory properties. The present study aimed to investigate the effect and mechanism of Tyr on lipopolysaccharide (LPS)-induced acute lung injury (ALI). In a mouse model, we found that pretreatment with Tyr significantly improved survival rate, attenuated lung permeability, ameliorated histopathological alterations, reduced expression of the inflammatory mediators and improved expression of the antioxidant enzyme. Further study revealed that Tyr markedly inhibited nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) activation at both in vivo and in vitro levels. To investigate the underlying mechanism, we examined the impact of Tyr on the heme oxygenase (HO)-1/nuclear factor erythroid-2 related factor 2 (Nrf2) pathway in vivo and in vitro. The results showed that Tyr significantly improved the expression of HO-1 and the activation of Nrf2. This study offers novel evidence to support the efficacy of Tyr against ALI, which helps to clarify the underlying causes of the therapeutic effects behind Tyr.
Collapse
Affiliation(s)
- Wen-Chen Wang
- Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University
| | - Yan-Min Xia
- Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University
| | - Bo Yang
- Department of Thoracic Surgery, Tianjin First Center Hospital
| | - Xiang-Ni Su
- Department of Nursing, Fourth Military Medical University
| | - Jia-Kuan Chen
- Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University
| | - Wei Li
- Department of Histology and Embryology, Fourth Military Medical University
| | - Tao Jiang
- Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University
| |
Collapse
|
6
|
Xu X, Si L, Xu J, Yi C, Wang F, Gu W, Zhang Y, Wang X. Asiatic acid inhibits cardiac hypertrophy by blocking interleukin-1β-activated nuclear factor-κB signaling in vitro and in vivo. J Thorac Dis 2015; 7:1787-97. [PMID: 26623102 DOI: 10.3978/j.issn.2072-1439.2015.10.41] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND Activated interleukin (IL)-1β signaling pathway is closely associated with pathological cardiac hypertrophy. This study investigated whether asiatic acid (AA) could inhibit IL-1β-related hypertrophic signaling, and thus suppressing the development of cardiac hypertrophy. METHODS Transverse aortic constriction (TAC) induced cardiac hypertrophy in C57BL/6 mice and cultured neonatal cardiac myocytes stimulated with IL-1β were used to evaluate the role of AA in cardiac hypertrophy. The expression of atrial natriuretic peptide (ANP) was evaluated by quantitative polymerase chain reaction (qPCR) and the nuclear factor (NF)-κB binding activity was measured by electrophoretic mobility shift assays (EMSA). RESULTS AA pretreatment significantly attenuated the IL-1β-induced hypertrophic response of cardiomyocytes as reflected by reduction in the cardiomyocyte surface area and the inhibition of ANP mRNA expression. The protective effect of AA on IL-1β-stimulated cardiomyocytes was associated with the reduction of NF-κB binding activity. In addition, AA prevented TAC-induced cardiac hypertrophy in vivo. It was found that AA markedly reduced the excessive expression of IL-1β and ANP, and inhibited the activation of NF-κB in the hypertrophic myocardium. CONCLUSIONS Our data suggest that AA may be a novel therapeutic agent for cardiac hypertrophy. The inhibition of IL-1β-activated NF-κB signaling may be the mechanism through which AA prevents cardiac hypertrophy.
Collapse
Affiliation(s)
- Xiaohan Xu
- 1 Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Institute of Integrated Medicine, Nanjing Medical University, Nanjing 210029, China ; 3 Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng 224005, China ; 4 Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 5 Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China
| | - Linjie Si
- 1 Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Institute of Integrated Medicine, Nanjing Medical University, Nanjing 210029, China ; 3 Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng 224005, China ; 4 Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 5 Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China
| | - Jing Xu
- 1 Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Institute of Integrated Medicine, Nanjing Medical University, Nanjing 210029, China ; 3 Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng 224005, China ; 4 Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 5 Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China
| | - Chenlong Yi
- 1 Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Institute of Integrated Medicine, Nanjing Medical University, Nanjing 210029, China ; 3 Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng 224005, China ; 4 Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 5 Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China
| | - Fang Wang
- 1 Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Institute of Integrated Medicine, Nanjing Medical University, Nanjing 210029, China ; 3 Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng 224005, China ; 4 Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 5 Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China
| | - Weijuan Gu
- 1 Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Institute of Integrated Medicine, Nanjing Medical University, Nanjing 210029, China ; 3 Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng 224005, China ; 4 Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 5 Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China
| | - Yuqing Zhang
- 1 Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Institute of Integrated Medicine, Nanjing Medical University, Nanjing 210029, China ; 3 Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng 224005, China ; 4 Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 5 Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China
| | - Xiaowei Wang
- 1 Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 2 Institute of Integrated Medicine, Nanjing Medical University, Nanjing 210029, China ; 3 Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng 224005, China ; 4 Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 5 Department of Cardiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, China
| |
Collapse
|
7
|
Ding Y, Shi X, Shuai X, Xu Y, Liu Y, Liang X, Wei D, Su D. Luteolin prevents uric acid-induced pancreatic β-cell dysfunction. J Biomed Res 2014; 28:292-8. [PMID: 25050113 PMCID: PMC4102843 DOI: 10.7555/jbr.28.20130170] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2013] [Revised: 12/07/2013] [Accepted: 01/16/2014] [Indexed: 11/24/2022] Open
Abstract
Elevated uric acid causes direct injury to pancreatic β-cells. In this study, we examined the effects of luteolin, an important antioxidant, on uric acid-induced β-cell dysfunction. We first evaluated the effect of luteolin on nitric oxide (NO) formation in uric acid-stimulated Min6 cells using the Griess method. Next, we performed transient transfection and reporter assays to measure transcriptional activity of nuclear factor (NF)-κB. Western blotting assays were also performed to assess the effect of luteolin on the expression of MafA and inducible NO synthase (iNOS) in uric acid-treated cells. Finally, we evaluated the effect of luteolin on uric acid-induced inhibition of glucose-stimulated insulin secretion (GSIS) in Min6 cells and freshly isolated mouse pancreatic islets. We found that luteolin significantly inhibited uric acid-induced NO production, which was well correlated with reduced expression of iNOS mRNA and protein. Furthermore, decreased activity of NF-κB was implicated in inhibition by luteolin of increased iNOS expression induced by uric acid. Besides, luteolin significantly increased MafA expression in Min6 cells exposed to uric acid, which was reversed by overexpression of iNOS. Moreover, luteolin prevented uric acid-induced inhibition of GSIS in both Min6 cells and mouse islets. In conclusion, luteolin protects pancreatic β-cells from uric acid-induced dysfunction and may confer benefit on the protection of pancreatic β-cells in hyperuricemia-associated diabetes.
Collapse
Affiliation(s)
- Ying Ding
- Center of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Xuhui Shi
- Center of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Xuanyu Shuai
- Center of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Yuemei Xu
- Center of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Yun Liu
- Center of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Xiubin Liang
- Center of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Dong Wei
- Department of Endocrinology, the Second People's Hospital of Chengdu, Sichuan 610017, China
| | - Dongming Su
- Center of Metabolic Disease Research, Nanjing Medical University, Nanjing, Jiangsu 210029, China. ; Center of Cellular Therapy, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
| |
Collapse
|